EGFR-TKIs have been established for patients with advanced NSCLC harboring EGFR mutations, with 3 generations of TKIs showing improvement in progression-free survival (PFS) compared with chemotherapy.3 Based on the success in the advanced stage, EGFR-TKIs were assessed in the adjuvant setting. Here, EGFR is linked to non-small cell lung carcinoma.